Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246NCT03268382Aprea TherapeuticsPhase 2Completed2019-07-10Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.